Literature DB >> 15345107

Prevalence of major depression one year after predictive testing for Huntington's disease.

Ann-Marie Codori1, Phillip R Slavney, Adam Rosenblatt, Jason Brandt.   

Abstract

Psychiatric hospitalizations, completed suicides, and suicide attempts are rare after predictive testing for Huntington's disease (HD). Case studies have shown that major depression can be a consequence of being tested, although no studies have shown how common this is. The present study evaluated the prevalence of major depression during the first year after disclosure. We conducted retrospective data and chart reviews of 153 persons (50 testing positive, 103 testing negative) evaluated every 3 months for depression. There was no significant baseline difference in the percentage of "positives" and "negatives" who had pre-testing major depressive episodes (14% vs. 12%, respectively). A senior psychiatrist reviewed data from the Schedule for Affective Disorders and Schizophrenia-Change Version, from the Beck Depression Inventory, and from clinical notes for every follow-up contact completed. The 1-year prevalence of major depression among positives was 6.0%, compared to 3.0% among negatives (p = 0.30), and an estimated 3% population prevalence. One-year prevalence of clinically significant depressive symptoms, whether or not major depression was diagnosed, was 20.0% in positives and 12.6% in negatives (p = 0.17). Although not statistically significant, depressive symptoms and major depression occurred more frequently among those who tested positive. Despite some evidence to the contrary, including our own studies, a positive predictive test for HD is not psychologically benign. Clinical testing programs should assess patients for depressive symptoms after testing, and patients with clinically significant complaints should be referred to a mental health professional.

Entities:  

Mesh:

Year:  2004        PMID: 15345107     DOI: 10.1089/gte.2004.8.114

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  11 in total

1.  The right to ignore genetic status of late onset genetic disease in the genomic era; Prenatal testing for Huntington disease as a paradigm.

Authors:  A Erez; K Plunkett; V R Sutton; A L McGuire
Journal:  Am J Med Genet A       Date:  2010-07       Impact factor: 2.802

2.  Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study.

Authors:  Maria U Larsson; Mary A Luszcz; The-Hung Bui; Tarja-Brita Robins Wahlin
Journal:  J Genet Couns       Date:  2006-10       Impact factor: 2.537

3.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

4.  Prospective Evaluation of Predictive DNA Testing for Huntington's Disease in a Large German Center.

Authors:  Aysegül Ibisler; Sebastian Ocklenburg; Susanne Stemmler; Larissa Arning; Jörg T Epplen; Carsten Saft; Sabine Hoffjan
Journal:  J Genet Couns       Date:  2017-03-30       Impact factor: 2.537

5.  Psychological Impact of Predictive Genetic Testing in VCP Inclusion Body Myopathy, Paget Disease of Bone and Frontotemporal Dementia.

Authors:  Abhilasha Surampalli; Manaswitha Khare; Georgette Kubrussi; Marie Wencel; Jasmin Tanaja; Sandra Donkervoort; Kathryn Osann; Mariella Simon; Douglas Wallace; Charles Smith; Aideen M McInerney-Leo; Virginia Kimonis
Journal:  J Genet Couns       Date:  2015-02-26       Impact factor: 2.537

6.  Psychological follow-up of presymptomatic genetic testing for spinocerebellar ataxia type 2 (SCA2) in Cuba.

Authors:  Milena Paneque; Carolina Lemos; Karell Escalona; Lizandra Prieto; Rubén Reynaldo; Mercedes Velázquez; Judith Quevedo; Nieves Santos; Luis Enrique Almaguer; Luis Velázquez; Alda Sousa; Manuela Fleming; Jorge Sequeiros
Journal:  J Genet Couns       Date:  2007-02-23       Impact factor: 2.537

7.  A prospective, longitudinal study of the impact of GJB2/GJB6 genetic testing on the beliefs and attitudes of parents of deaf and hard-of-hearing infants.

Authors:  Christina G S Palmer; Ariadna Martinez; Michelle Fox; Jin Zhou; Nina Shapiro; Yvonne Sininger; Wayne W Grody; Lisa A Schimmenti
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

Review 8.  Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Authors:  Xin Du; Terence Y Pang
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

9.  A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.

Authors:  Xin Du; Terence Y C Pang; Anthony J Hannan
Journal:  Front Neurol       Date:  2013-07-09       Impact factor: 4.003

10.  Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD).

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Matthew W Roché; Rebecca E Ready; Joel S Perlmutter; Kelvin L Chou; Stacey K Barton; Michael K McCormack; Julie C Stout; David Cella; Jennifer A Miner; Jane S Paulsen
Journal:  Qual Life Res       Date:  2020-08-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.